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1. Introduction 
The antiphospholipid syndrome (APS) is a multisystemic disease, characterized by venous 
or arterial thromboses, or certain obstetric complications, and the presence of 
antiphospholipid antibodies (APAs)(1-4). APAs are a heterogeneous group of autoantibodies 
that bind to negatively charged phospholipids, phospholipid-binding protein, or a 
combination of the two. Lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and 
anti-beta 2 glycoprotein 1 (anti-β2GP1) antibodies are the main antibodies in this 
syndrome(1;2;5). APS occurs in isolation as a primary APS in more than 50% of the cases, but 
can be associated with other autoimmune diseases, most often with systemic lupus 
erythemathosus (SLE). Twenty to 35% of women with SLE develop APS(6). APS occurs for 
the most part in young women of fertile age(7). It occurs rarely in children, and only 12% of 
all APS occur after 50 years of age(8).  
2. Antiphospholipid antibodies in pregnancy 
Antiphospholipid antibodies in pregnancy are associated with recurrent miscarriage, 
intrauterine growth restriction (IUGR), preeclampsia, placental abruption, premature 
delivery or fetal death in addition to arterial or venous thrombosis(9;10). Thus, the woman 
may experience both early and late fetal loss. Vascular thrombosis can occur in any organ or 
tissue(2).  Deep vein thrombosis in the legs is most frequent, but the renal vein, the 
pulmonary vein, the inferior vena cava and the hepatic and portal vein may also be affected. 
The most common site of arterial thrombosis is the cerebral circulation, but occlusion of 
coronary and retinal arteries has also been reported(3;11;12). APA, particularly LA, is an 
independent risk factor for first and possibly recurrent ischemic stroke in young adults(13). 
Cerebral ischemic events can occur in any vascular territory(14). Cerebral angiography 
typically demonstrates intracranial branch or trunk occlusion or is normal in about one third 
of patients so studied(15). In addition, leg ulcer, chorea, and migraine have been associated 
with APAs(3). A wide range of abdominal manifestations have been reported in APA-
positive patients. Hepatic involvement is most numerous, thereafter thrombotic events in 
branches of the intestinal vasculature(16). 
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3. Diagnosis of APS in non-pregnant and pregnant women 
According to the last updated consensus the diagnosis of obstetric APS needs to be based 
on: 1) one or more unexplained deaths of normal fetuses at or beyond the 10th week of 
gestation, or 2) one or more premature births before the 34th week of gestation because of 
eclampsia, severe preeclampsia, or placental insufficiency, or 3) three or more unexplained 
consecutive spontaneous abortions before the 10th gestational week(7). Pregnant women 
with such complications should have laboratory testing. 
The diagnosis of APS must be based both on clinical criteria and persistent positivity for 
APA(2;7). Laboratory testing for APA is used to confirm or refute the diagnosis(2). Thrombosis 
must be confirmed by strict objective criteria (angiography, venography, Doppler 
ultrasound examination or CT)(7). CT is considered to be first-line investigation of suspected 
thrombosis in patients with abdominal symptoms. CT features of mesenteric ischemia are 
thickening of both small and large bowel walls with prominence of the supplying 
mesenteric vessels(17). For histopathological confirmation thrombosis should be present 
without evidence of inflammation in the vessel wall(7). Cerebral thrombosis can be 
diagnosed by cerebral angiography, transcranial Doppler technique, or magnetic resonance 
imaging (MRI)(13;18). In some cases, MRI has revealed small foci of high signal in subcortical 
white matter scattered throughout the brain(13;19). 
4. Venous thromboembolism 
Pregnancy is a risk factor for venous thromboembolism (VTE). From two to ten-fold increase 
of VTE compared with the risk for non-pregnant women has been reported(20;21).The risk 
of thrombosis in the lower extremities may be even higher in women with coexisting risk 
factors (e.g. obesity, thrombophilia or acquired APS)(22;23). Women with APS are at high risk 
of recurrent thrombosis(24), and this risk may even be higher in pregnant women(21). A 
retrospective comparison of the overall risk of recurrence of VTE revealed risk of 11% per 
100 patient-years during pregnancy and 3.7% in the non-pregnant state (the risk ratio for 
VTE during pregnancy was 3.5 with 95% confidence interval (CI) 1.6-7.8)(25). Although a 
clear association between APAs and vascular events has been described, the data from a 
cohort study did not support that aCL antibodies affect vascular mortality(26). 
5. Catastrophic APS 
Catastrophic APS (CAPS), also known as “Asherson’s syndrome”) is an unusual (<1%) 
variant of APS, which is characterised by rapid appearance of multiple thromboses (mainly 
small-vessel thrombosis) that lead to multiorgan failure(27). It is an acute, life-threatening, 
complication which may occur both in non-pregnant and pregnant women(28).  
Diagnostic algorithms which have been proposed include the occurence of new thromboses 
in at least three different organs in less than a week(29). In patients with a history of APS or 
persistent APA-positivity as described in the guidelines, a diagnosis of definite CAPS is 
made if the patient has new thrombosis in at least three organs, with micro-thrombosis 
confirmed by biopsy(29). If only two organs are affected, or if confirmation with biopsy is not 
available, a diagnosis of probable CAPS is made. If the patient does not have a history of 
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Disseminated intravascular coagulation occurs in approximately 25% of patiens with 
CAPS(30). In more than 50% of the cases, catastrophic events are triggered by infections, 
trauma or surgery, anticoagulation withdrawal, malignancies, lupus “flares” or obstetric 
complications(28).  
CAPS may infrequently appear during pregnancy after a Caesarean section or fetal loss(28). 
The HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) may be part of the 
catastrophic syndrome(31). Bone marrow necrosis and a refractory HELLP syndrome have 
been reported in a woman with catastrophic APS. The fetus died in spite of termination of 
pregnancy(32). A retrospective study comprised 15 cases of catastrophic APS in pregnancy or 
puerperium. APS was primary in 7 while 8 had SLE or lupus-like disease. In 8 of 15 cases  
(53%) the catastrophic syndrome were associated with HELLP syndrome. Six cases (43%) 
occurred in the puerperium and 1 after fetal death(28).  
Laboratory testing 
Transient occurrence of APA may not be associated with increased risk for clinical events. 
Therefore, it is essential that a positive test for APA is repeated after at least 12 weeks to 
confirm diagnostic citeria(7). 
LA assays are functional assays based on one of several phospholipid-dependent clotting 
tests(10). LA seems to be the most specific test for APS(33). LA is strongly associated with fetal 
loss at more than 10 weeks’ gestation. In a metaanalysis on women without autoimmune 
disease, LA was associated with late recurrent fetal loss (at least 2 fetal losses) with odds 
ratio 7.8 (95% CI 2.3-26.5)(34). Positive tests for APAs are found in 2% of the general 
population and in 30-40% of patients with SLE(12;35). In general obstetric clinics the 
prevalence of APAs has been reported to be between 2.7% and 7%(36). 
aCL antibodies are detected by enzyme linked immunoabsorbent assays (ELISAs) that 
measure anti-β2GP1 antibody dependent IgG and IgM aCL antibodies(2;7;37). The aCL ELISA 
test has high sensitivity, but low specificity(8) and skill and experience are necessary in 
interpreting the results(4). Despite international efforts to standardize laboratory testing 
significant variation in the performance of APS antibody assays in laboratories remains a 
critical problem(2). 
In 1990 three independent groups reported that aCL antibodies were directed against the 
plasma protein β2GP1(38-40). Several commercial ELISA assays for the detection of anti-
β2GP1 antibodies of IgG and IgM type have later been developed. However, the laboratory 
detection of APAs by ELISA tests has been flawed by lack of standardisation and 
disconcordant results between manufacturers and laboratories(41). The European Forum on 
Antiphospholipid Antibodies have published methodological analyses and proposals for 
the performance of these assays(42;43). 
To exclude the presence of APAs, both clotting-based assays for LA and ELISA tests for anti-
β2GP1/aCL should be performed(7). LA-testing should be performed according to guidelines 
published as an official communication of the Scientific Standardization Committee of the 
International Society on Thrombosis and Haemostasis(44). The latest consensus on classification 
criteria for APS states that cut-off for positive aCL and/or anti-β2GP1 tests should be >99th 
percentile of the titres in a reference group or, for aCL antibodies, should be present in 
medium or high titre (>40 IgG or IgM phospholipid units)(7).  
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6. Thrombocytopenia in patients with APS 
APS related thrombocytopenia is defined by a platelet count less than 100·109/L, confirmed 
twice 12 weeks apart, and is found in approximately 20% of patients with APS and in more 
than 40% of patients who have APS associated with underlying SLE(45). A minority of 
patients have thrombocytopenia with platelets less than 50·109/L(45). APS-associated 
thrombocytopenia is an autoimmune phenomenon and its relation to thrombotic risk is 
poorly characterized. However, thrombocytopenia does not appear to reduce thrombotic 
risks in patients with APS(45). 
7. Distinguishing APS from other prothrombotic and thrombocytopenic 
conditions 
The differential diagnosis in patients presenting with thrombocytopenia includes 
thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT) and 
DIC(45). Distinguishing these conditions can be challenging. Diagnosing APS requires 
documentation of persistent APA antibodies in combination with compatible clinical 
features of thrombosis or pregnancy morbidity. However, APA antibodies have been 
documented in TTP and other thrombotic microangiopathies including haemolytic uremic 
syndrome and HELLP  syndrome(16), as well as in cases of HIT. Patients with TTP present 
with microangiopathic hemolytic anaemia, typically manifesting with schistocytes on the 
blood smear and evidence of hemolysis, which is not a typical feature in APS. Measurement 
of the ADAMTS-13 metalloprotease, if available, may be helpful in these situations given 
that TTP is associated with ultra-large von Willebrand factor multimers that result from a 
deficiency in ADAMTS-13. If the patient is under medication with heparin, HIT must be 
considered. Notably, false-positive HIT antigen tests can be distinguished from true HIT 
antibodies by using enzyme immunoassays for PF4/heparin complexes tested with heparin 
excess or with use of functional assays(46). Patients with DIC typically have negative tests for 
APAs, frequently with evidence of thrombocytopenia, coagulopathy and thrombotic or 
hemorrhagic complications(45). Patients with severe DIC have low platelet count, fibrinogen 
and antithrombin (consumption coagulopathy). 
8. Thrombotic microangiopathic hemolytic anaemia (TMHA) and APS 
The term thrombotic microangiopathic hemolytic anaemia (TMHA) was introduced by 
Symmers in 1952 to describe clinical disorders related to the presence of localised or diffuse 
microvascular thrombosis(47). TMHA is characterised by thrombocytopenia, 
microangiopathic hemolytic anaemia (as indicated by erythrocyte fragmentation on 
peripheral blood smears) accompanied by a negative Coombs’ test, fever, neurological 
symptoms, and kidney involvement(48). Several reports have pointed out the relationship of 
TMHA with the presence of APAs(48). SLE was the first autoimmune disease in which the 
association of TMHA with APA was recognised(48). There is evidence to support the 
hypothesis that TMHA might be a manifestation of APS(48). 
9. APS, preeclampsia and the HELLP syndrome 
A systematic literature search for the association of aCL antibodies with preeclampsia 
generated 68528 abstracts and 64 full-text articles (7). Inclusion criteria were cohort-, case-
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control or controlled cross-sectional-studies comprising women with no autoimmune 
diseases but with IgG or IgM aCL antibody of at least 20 units, or both, with preeclampsia as 
endpoint. Twelve studies were included in a meta-analysis. The study comprised 
publications from before 2006 (when new criteria were established) and thus did not 
consider the latest antiphospholipid criteria when addressing aCL cut-off levels in the final 
analysis(7). Different methods of diagnosing preeclampsia were used in these 12 
publications. The severity of preeclampsia was not stated in 7 of the publications. Pooled OR 
for association of aCL antibodies with preeclampsia was 2.9 (95% CI 1.4-5.9)(5). Pooled OR 
for aCL antibodies and severe preeclampsia was 11.2 (95 % CI 2.7-46.8). It was concluded 
that moderate-to-high levels of aCL antibodies were associated with preeclampsia. There 
was, however, insufficient evidence to advocate use of aCL antibodies as predictors of 
preeclampsia(5).  
Branch and Khamashta reported in 2003 that in women with SLE and prior thrombosis the 
median rate of preeclampsia was 32% ranging up to 50%; that of preterm births ranged from 
32% to 65%(2). One study suggested that the second trimester Doppler ultrasound 
examination may be the best predictor of late pregnancy outcome in SLE and/or the APS(49).  
Women with APAs seem to have increased risk of developing a HELLP syndrome(31;50-52). 
One series, that comprised 75 pregnancies with primary or secondary APS, included 7 
women who had 8 episodes of HELLP(53). A retrospective analysis of 16 episodes of HELLP 
complicating APS comprised 15 women. APS was primary in 9 women and secondary in 6 
cases(31). The HELLP syndrome was complete in 10 episodes and partial in 6, occurring in 
the second trimester (44%) in 7 cases (the earliest at 18 weeks’ gestation), and 12.5% at 18-20 
weeks(31). The outcome was 8 live births, 2 stillbirths and 6 fetal deaths(31). Backos et al. 
reported two cases of a HELLP syndrome in a series of 150 pregnancies in women with 
recurrent miscarriages and APAs(54). In a placebo controlled study of intravenous 
immunoglobulin treatment for APS, Branch et al. observed that 6 out of 16 women with APA 
developed severe preeclampsia and/or HELLP(55). In a literature review of well described 
cases of HELLP complicating APS, HELLP occurred before 27 weeks’ gestation in most 
cases. The HELLP syndrome occurred as early as the 8th week of gestation(56). Thus, HELLP 
appears to develop earlier in women with APS than in women in the general population. 
The condition also tends to be more severe(31). 
In the cases of HELLP syndrome associated with APS published by Le Thi Thoung et al. no 
case of liver infarction was observed(31). Pauzner et al., on the other hand, found liver infarcts 
to be almost always associated with APS in women with a HELLP syndrome(56). Pauzner et 
al. also reviewed 30 pregnancies in 28 women with pregnancy-associated hepatic infarcts. 
APA were present in 15 of 16 patients with available data, 16 had typical HELLP syndrome. 
Almost all patients with hepatic infarcts were APA positive in addition to suffering from 
complete or atypical HELLP syndrome. Hepatic infarcts occurred at all stages of 
pregnancy(57). In APA positive women the HELLP syndrome usually occurs during the 
second trimester of pregnancy; one-third of these develop hepatic infarcts(58). 
10. Pathogenesis of APS 
Habitual abortions (defined as ≥3 spontaneous consecutive pregnancy losses) affect 1-2% of 
women in reproductive age. Up to 5% of women in reproductive age have ≥2 recurrent 
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abortions(59). APA antibodies have also been implicated in first trimester miscarriage(60). 
Deleterious effects of APA antibodies in women with recurrent abortions is extended to pre-
embryonic and embryonic losses(30). APA may impair both trophoblast invasion in the 
decidua and the spiral arteries and the placental hormone production and cause utero-
placental insufficiency and fetal loss(30).  
Serbie et al. examined the products of consumption from early pregnancy failures in women 
with recurrent fetal loss to investigate the mechanism of pregnancy loss(61). There were 31 
primary APS-positive, 50 APA-negative, 34 aneuploid and 20 control cases with termination 
of pregnancy for social reasons at 6-14 weeks gestation. Chorionic villous morphology and 
frequency of intervillous thrombosis were not different among groups. Normal decidual 
and endovascular trophoblast invasion in the spiral ateries was identified significantly less 
frequent in primary APA-positive cases (24%), compared with controls (75%), aneuploid 
(53%), or APA-negative cases (61%; Z=-3.0, P <0.01)(61). Chorionic villous morphology and 
intervillous thrombosis were not different among the groups. Normal decidual and 
endovascular trophoblast invasion in spiral ateries was identified significantly less frequent 
in primary APA-positive cases (24%), than in controls (75%), aneuploid (53%), or APA-
negative cases (61 %). It was concluded that defective decidual and spiral atery 
endovascular trophoblast invasion, rather than excessive intervillous thrombosis, is the most 
frequent histological abnormality in primary APA-positive women with early pregnancy 
loss(61). In recurrent miscarriage with APAs, 20-60% of the aborted foetuses are 
chromosomally abnormal, and chromosomal anomalies as cause of fetal loss must be 
considered also in APA positive patients(4;62;63).  
There is a variety of mechanisms by which APA antibodies may cause pregnancy loss. APA 
antibodies may interfere with the normal in vivo function of phospholipids or phospholipid-
binding proteins that are crucial to regulation of coagulation(2). Tissue factor (TF), the major 
cellular initiator of the coagulation protease cascade, plays important roles in both 
thrombosis and inflammation(64). In-vitro studies have shown that certain APAs, specifically 
those directed against β2GP1, induce expression of TF(37;65). APAs also dysregulate the 
fibrinolytic system by cross-linking with annexin II (profibrinolytic endothelial cell surface 
receptor) on the endothelial cell surface inducing increased expression of TF(64). 
Autoantibodies have a causative role in monocyte TF expression. Growing evidence 
suggests that APA-dependent induction of TF activity on circulating blood monocytes is an 
important mechanism of hypercoagulability in APS(64). TF acting as an pro-inflammatory 
molecule enhances neutrophil activity which may cause trophoblast injury, placental 
dysfunction and damage to the embryo(64). Activated neutrophiles release reactive oxygen 
species and proteolytic enzymes leading to decidual damage(64).  Complement C3 and C5 
play a role in APA-induced thrombosis(64). In vitro and animal studies have shown that 
APAs can bind directly to trophoblasts cells and cause cellular injury, defective extravillous 
cytotrophoblast (EVT) invasion (in the decidua and spiral arteries), and induce a local 
inflammatory response as a result of activation of complement(8). Activation of complement 
and recruitment of inflammatory cells within the decidual tissues are necessary steps in 
APA-induced pregnancy loss(66).  
The negative effect of APS on pregnancy is most likely tied to abnormal placental function(2). 
Adverse pregnancy outcomes in women with APS may result from poor placental perfusion 
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due to localised thrombosis, perhaps through interference by APA antibodies with 
trophoblastic annexin V(30). 
Some investigators have found narrowing of spiral arteries, intimal thickening, acute 
atherosis and fibrinoid necrosis in the placenta of women with fetal loss associated with 
APS. Others have found extensive placental necrosis, infarctions and thrombosis(2). APAs 
may activate endothelial cells as indicated by increased expression of adhesion molecules, 
secretion of cytokines, and production of arachidonic acid metabolites(2).  
The pathogenesis of APA-mediated thrombosis probably involves several pathogenic 
mechanisms including thrombogenic microparticles derived from maternal endothelial cells, 
platelets and trophoblasts(67). Other mechanisms are inhibition of the natural antithrombotic 
proteins, such as protein C, TF pathway inhibitor, annexin V, activation of the complement 
system and impairment of fibrinolysis which regulate thrombus remodelling and 
dissolution(68). 
Vitamin D is essential for calcium and bone mineralism, but is also a mediator of many other 
effects such as modulation of the immune response, being able to combat certain 
microorganisms(69). Vitamin D deficiency has been reported to be common among patients 
with APS and is associated with clinically defined thrombotic events. Vitamin D deficiency 
(serum level ≤ 15 ng/ml) occured in 50% of cases with APS compared to 30% of control 
subjects significantly correlating with thrombosis, neurological and ophthalmic 
manifestations, pulmonary hypertension, livedo reticularis (a vascular condition 
characterized by purplish mottling of the skin) and skin ulcers(69). An inverse correlation 
between vitamin D levels and thrombosis was found in this cohort(69). Vitamin D is a potent 
inhibitor of the anti-β2GPI antibody-mediated expression of TF induced by endothelial 
cells(69). Thus, vitamin D deficiency might be associated with decreased inhibition of TF 
expression and increased coagulation in APS.  
Studies have also shown that inflammatory mechanisms in the placental bed may contribute 
to APS(64). Some studies suggest that APA induce a pro-coagulant response in endothelial 
cells and monocytes through interaction with toll-like receptor- 4 (TLR-4)(64). 
11. Therapeutic options 
Over a long period treatment of APS included low-dose aspirin either alone or combined 
with prednisone, unfractioned heparin or low molecular weight heparin (LMWH), 
intravenous immunoglobulin infusion or plasma exchange(36). Warfarin crosses the placenta 
and is teratogenic in the first trimester(8). Women, who are on long- term warfarin treatment 
because of previous thrombosis, should switch to heparin when trying to conceive or when 
pregnancy is confirmed(8). In high risk groups, such as women with mechanical heart valves, 
warfarin may be used in pregnancy, but only after organogenesis (6th-12th week) because of 
high risk of fetal malformations(3). Warfarin treatment is however, also associated with 
spontaneous abortions, prematurity and CNS abnormalities(70). As warfarin cross the 
placenta and subsequently affect fetal coagulation, there is a risk for bleeding complications 
in the fetus and during birth(71).In the Cochrane review by Empson et al. it was concluded 
that a combination therapy with heparin and aspirin may reduce pregnancy loss in women 
with APA by 54%(36). Heparin combined with aspirin reduced the pregnancy loss more than 
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aspirin alone (relative risk (RR) 0.46; 95% CI 0.29-0.71)(36). In the trials of prednisone and 
aspirin, no benefit was shown, rather a significant increase in prematurity (RR 4.83; 95% CI 
2.85-8.21)(36). In addition, prednisone was also associated with a 3.5-fold (95% CI 1.5-8.2) 
greater risk of gestational diabetes than aspirin alone, heparin and aspirin, or placebo(72-74). 
Prednisone appears to have no role in the treatment of recurrent pregnancy loss associated 
with APA antibodies(36). 
Current management of APS in pregnancy generally includes heparin combined with 
aspirin. LMWHs are at least as effective as unfractioned heparin and are safer(21;71). The 
rationale of this combination is that aspirin may inhibit APA mediated hypercoagulopathy 
in the intervillous space of the placenta while heparin may prevent APA from interfering 
with cytotrophoblast migration and promote blastocyst implantation in addition to 
prevention of venous thrombosis(75).  
Prolonged heparin treatment may induce osteoporosis. Recently, there has been a move 
towards low molecular weight heparin because of the advantages of daily dosing and a 
perception that it may have less effect on bone mineral density than heparin(36). 
The pregnancy- associated prothrombotic changes in the coagulation system are maximal 
immediately after delivery(21). Despite lack of controlled studies regarding duration of 
anticoagulation, it is well accepted that persistent APA-positive women require post-partum 
anticoagulation. Therefore, it is desirable to continue LMWH during labor or delivery in 
women receiving antenatal thromboprophylaxis(21). The duration of recommendations range 
from 3-5 days(21), to 6-8 weeks(76) and up to 12 weeks(77). 
12. Use of anticoagulants in lactating women 
Heparin and LMVHs are not secreted into breast milk and can be safely given to nursing 
mothers. Warfarin is safe after delivery and for breast feeding, althogh it requires close 
monitoring, frequent visits to an anticoagulant clinic and carries an increased risk of 
postpartum hemorrhage and perineal hematoma compared with LMWH (21). Warfarin does 
not induce an anticoagulant effect in the breast-fed infant. Therefore, the use of warfarin in 
women who require postpartum anticoagulation therapy is safe and these women should be 
encoraged to breast feed(78). 
No randomised controlled trials have investigated prevention in women with a history of 
late miscarriage, fetal death and IUGR. Most obstetricians would consider treatment with 
low-dose aspirin and prophylactic dose of (low molecular weight) heparin in such cases. In 
women with APA antibodies, and a history of severe preeclampsia, at least low dose aspirin 
(75-80 mg once a day) is recommended(79). Glucorticoids, cytotoxic agents, and intravenous 
immunoglobulin have no confirmed benefit and should not be used to treat pregnant 
women with APS(79). 
13. Contraception after birth 
Oral estrogen coating contraceptives increase the maternal thrombotic risk of women with 
APAs and SLE(80). Therefore, intrauterine devices are probably more appropriate. However, 
progesterone-only contraceptives do not increase the risk of thrombosis(81). If a woman with 
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APS wants to be pregnant again, pre-conceptional treatment deserves consideration42. Some 
women with APS may need life-long warfarin treatment. 
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